ClinicalTrials.Veeva

Menu

The Effect of Blood Pressure on Cerebral Perfusion During Vascular Surgery

Rigshospitalet logo

Rigshospitalet

Status

Withdrawn

Conditions

Peripheral Arterial Diseases
Anesthesia

Treatments

Other: MAP maintained at 60 mmHg
Other: MAP maintained at 80 mmHg

Study type

Interventional

Funder types

Other

Identifiers

NCT02531139
NDOlesen

Details and patient eligibility

About

Anesthesia reduces blood pressure and cerebral blood flow is normally considered to be maintained despite marked changes in blood pressure. Vascular surgical patients are often elderly, have high blood pressure and atherosclerosis and in these patients cerebral blood flow may decrease if blood pressure is reduced during anesthesia. The purpose of this study is to assess the effect of blood pressure for preservation of cerebral blood flow during anesthesia in vascular surgery. The hypothesis is that in vascular surgical patients, during anesthesia, cerebral blood flow is higher with blood pressure maintained at a higher level than that used in normal clinical practice.

Full description

Background: Induction of anesthesia reduces mean arterial pressure (MAP) and cerebral blood flow is normally considered to be maintained by cerebral autoregulation despite changes in MAP between 60 - 150 mmHg and standard of care during anesthesia is to maintain MAP above 60 mmHg. Vascular surgical patients are often elderly with hypertension and atherosclerotic manifestations that may impair cerebral autoregulation of importance for anesthesia-induced reduction in blood pressure.

Objective: To assess the effect of MAP for preservation of cerebral blood flow and oxygenation during vascular surgery.

Hypothesis: The primary hypothesis is that during general anesthesia in vascular surgical patients, cerebral blood flow velocity and oxygenation is higher with MAP maintained at 80-90 mmHg, compared with a MAP maintained at a minimum of 60 mmHg.

MAP is controlled in both groups using continuous infusion of phenylephrine. Phenylephrine is used as a tool in order to assess the effect of MAP on the cerebral circulation. In both groups, central blood volume is optimized by infusion of lactated Ringer´s solution using a goal directed fluid therapy following induction of anaesthesia and before commencement of phenylephrine infusion.

Trial size: The investigators will include 40 participants (2 x 20) in order to detect or reject a 20% difference in middle cerebral artery velocity with a type I error risk of 5% and a type II error risk of 20% (power at 80%). Interim analysis will be conducted after inclusion of 20 patients (2 x 10). Excluded patients will be replaced.

Sex

All

Ages

19+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients undergoing one of the following vascular surgical interventions in general anesthesia: Infra-inguinal bypass, femoro-femoral cross-over bypass or iliofemoral bypass surgery.
  • Age > 18 years. Informed consent

Exclusion criteria

  • Use of monoamine oxidase inhibitors
  • Allergy to phenylephrine
  • Patients that cannot cooperate during examination
  • Dementia defined as Mini-Mental State Examination < 24
  • Anesthesia within the last 30 days
  • Alcohol consumption at or above 420 grams per week
  • Lack of fluency in written and spoken Danish
  • Severe hearing and vision impairment
  • Neurological disease

Trial design

Primary purpose

Supportive Care

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Triple Blind

0 participants in 2 patient groups

MAP maintained at 80 mmHg
Experimental group
Description:
During anesthesia MAP is maintained at 80 - 90 mmHg MAP using continuous infusion of phenylephrine.
Treatment:
Other: MAP maintained at 80 mmHg
MAP maintained at 60 mmHg
Active Comparator group
Description:
During anesthesia MAP is maintained at minimum of 60 mmHg using continuous infusion of phenylephrine.
Treatment:
Other: MAP maintained at 60 mmHg

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems